A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

This study is testing a new injectable medication called ARO-ALK7 as a potential treatment for obesity, with or without type 2 diabetes. ARO-ALK7 works by silencing a gene involved in fat storage. This is an early-phase trial focused on safety and how the drug behaves in the body. **You may be eligible if...** - You are an adult with obesity (BMI between 30 and 50) - You weigh under 159 kg (350 lbs) - You have tried and failed to lose weight through lifestyle changes at least once - You have no major health conditions that could affect your safety or study results **You may NOT be eligible if...** - Your weight has changed by more than 5% in the last 3 months - You have used GLP-1 medications (like semaglutide or liraglutide) in the past 6 months - You have used other prescription or over-the-counter weight loss medications recently - You have had weight loss surgery or a device-based obesity treatment before - Your obesity is mainly caused by medications or a hormonal/genetic condition Talk to your doctor to see if this trial is right for you.